Understanding the precise binding mode of XR5944 to a naturally occurring ERE sequence would provide an important basis for the design and development of DNA bis-intercalators specifically targeting ER–ERE interactions for new breast cancer therapeutics. The gene discussed is ESR1; the disease is breast cancer.